U.S. SECURITIES AND EXCHANGECOMMISSION

| Nevada                                                                  | 88-0507007                                |
|-------------------------------------------------------------------------|-------------------------------------------|
| (State or other jurisdiction      ofincorporation or      organization) | (IRS Employer Identification      Number) |

| Large accelerated      filer  ¨ | Accelerated      filer   ¨ |
|------------------------------------------------|------------------------------------------------|
| Non-accelerated      filer  ¨   | Smaller reporting      company  x    |

----

ONCOLIN THERAPEUTICS, INC. ANDSUBSIDIARIES

| Part I  | Financial      Information |
|---------|----------------------------|
|    |                       |   |   |
|    |                       |   |   |
|    | Item 1.                    | Financial      Statements |   |
|    |                       |   |   |
|    |                       | Consolidated Balance Sheets      (unaudited) June 30, 2008 and March 31,      2008 |        1 |
|    |                       |   |   |
|    |                       | Consolidated Statements of      Operations (unaudited) Three Months Ended June 30, 2008 and 2007, andI      nception (May 9, 2007) through June 30, 2008 |        2 |
|    |                       |   |   |
|    |                       | Consolidated Statements of Cash      Flow (unaudited) Three Months Ended June 30, 2008 and 2007, and Inception      (May 9, 2007) through June 30, 2008 |        3 |
|    |                       |      |   |
|    |                       | Notes to Unaudited Consolidated      Financial Statements | 4-5 |
|    |                       |   |   |
|    | Item 2.                    | Management’s Discussion and      Analysis of Financial Condition and Results of      Operations | 6 |
|    |                       |   |   |
|    | Item 3.                    | Quantitative and Qualitative      Disclosures About Market Risk | 6 |
|    |                       |   |   |
|    | Item 4.                    | Controls and      Procedures | 7 |
|    |                       |   |   |
| Part II | Other      Information     |   |
|    |                       |   |   |
|    | Item 2.                    | Unregistered Sales of Equity      Securities and Use of Proceeds | 8 |
|    |                       |   |   |
|    | Item 6.                    | Exhibits | 9 |
|    |                       |   |   |

----

----

PARTI.                      FINANCIALINFORMATION

|                                                                       |   | June 30,    2008 |       |   | March 31,    2008 |   |
|----------------------------------------------------------------------------|--------|------------------|------------|--------|-------------------|--------|
|                                                                       |   |             |       |   |              |   |
| ASSETS                                                                     |   |             |       |   |              |   |
|                                                                       |   |             |       |   |              |   |
| Cash and cash      equivalents                                             |   | $                | 473        |   |              | $      | 1,174 |   |
| Prepaid      expenses                                                      |   |             | -          |   |              |   | 30,750 |   |
| Deferred offering      costs                                               |   |             | 11,664     |   |              |   | 12,915 |   |
| Total current      assets                                                  |   |             | 12,137     |   |              |   | 44,839 |   |
| Property and equipment,      net                                           |   |             | 4,448      |   |              |   | 4,670 |   |
| Option agreement,      net                                                 |   |             | 4,445      |   |              |   | 11,111 |   |
| Totalassets                                                                |   | $                | 21,030     |   |              | $      | 60,620 |   |
|                                                                       |   |             |       |   |              |   |   |   |
| LIABILITIES AND SHAREHOLDERS'      DEFICIT                                 |   |             |       |   |              |   |   |   |
|                                                                       |   |             |       |   |              |   |   |   |
| Current      liabilities:                                                  |   |             |       |   |              |   |   |   |
| Accounts      payable                                                      |   | $                | 75,196     |   |              | $      | 109,188 |   |
| Accounts payable – related      parties                              |   |             | 124,197    |   |              |   | 111,783 |   |
| Accrued      liabilities                                                   |   |             | 147,572    |   |              |   | 124,730 |   |
| Stock    Payable                                                           |   |             | 90,000     |   |              |   | - |   |
| Notes payable – related      parties                                 |   |             | 32,000     |   |              |   | 410,000 |   |
| Total current      liabilities                                             |   |             | 468,965    |   |              |   | 755,701 |   |
|                                                                       |   |             |       |   |              |   |   |   |
| Long Term      Liabilities                                                 |   |             |       |   |              |   |   |   |
| Convertible notes payable, net of      discount of $375,931                |   |             | 22,054     |   |              |   | - |   |
| Total      liabilities                                                     |   |             | 491,019    |   |              |   | 755,701 |   |
| Shareholders'      deficit:                                                |   |             |       |   |              |   |   |   |
| Common stock, $.001 par value,      500,000,000 shares authorized,         |   |             |       |   |              |   |   |   |
| 42,481,993 and 42,069,533 shares      issued and outstanding, respectively |   |             | 42,482     |   |              |   | 42,069 |   |
| Additional paid-in      capital                                            |   |             | 1,520,841  |   |              |   | 999,530 |   |
| Deficit accumulated during the      development stage                      |   |             | (2,033,313 | )      |              |   | (1,736,680 | ) |
| Total shareholders’      deficit                                     |   |             | (469,989   | )      |              |   | (695,081 | ) |
| Total liabilities and      shareholders' deficit                           |   | $                | 21,030     |   |              | $      | 60,620 |   |

----

|                                                                          |   | Three Months Ended June      30, |       |   | Inception (May 9, 2007)      to |   |
|-------------------------------------------------------------------------------|--------|----------------------------------|------------|--------|---------------------------------|--------|
|                                                                          |   | 2008                             |       |   | 2007                            |   |   | June 30,    2008 |   |
|                                                                          |   |                             |       |   |                            |   |   |   |   |
| Revenue                                                                       |   | $                                | -          |   |                            | $      | - |   |   | $ | - |   |
|                                                                          |   |                             |       |   |                            |   |   |   |   |   |   |   |
| Costs and      expenses:                                                      |   |                             |       |   |                            |   |   |   |   |   |   |   |
|     Compensation      and related expenses                |   |                             | 51,800     |   |                            |   | 125,603 |   |   |   | 779,245 |   |
|     Office      administration                            |   |                             | 2,928      |   |                            |   | 200 |   |   |   | 16,287 |   |
|     Professional      fees                                |   |                             | 165,128    |   |                            |   | 12,444 |   |   |   | 439,763 |   |
|     Investor      relations                               |   |                             | 8,360      |   |                            |   | 549 |   |   |   | 280,864 |   |
|     Merger      expenses                                  |   |                             | -          |   |                            |   | 8,113 |   |   |   | 8,113 |   |
|     Impairment      of license agreement                  |   |                             | -          |   |                            |   | 80,100 |   |   |   | 80,100 |   |
|     Acquisition      costs of subsidiary                  |   |                             | -          |   |                            |   | - |   |   |   | 220,000 |   |
|     Depreciation      and amortization                    |   |                             | 6,888      |   |                            |   | - |   |   |   | 16,252 |   |
|     Other      expenses                                   |   |                             | 31,964     |   |                            |   | 23,269 |   |   |   | 137,303 |   |
|         Total      costs and expenses |   |                             | 267,068    |   |                            |   | 250,278 |   |   |   | 1,977,927 |   |
| Interest      expense                                                         |   |                             | 29,565     |   |                            |   | 4,663 |   |   |   | 55,386 |   |
| Net loss                                                                      |   | $                                | (296,633   | )      |                            | $      | (254,941 | ) |   | $ | (2,033,313 | ) |
|                                                                          |   |                             |       |   |                            |   |   |   |   |   |   |   |
| Net loss per      share:                                                      |   |                             |       |   |                            |   |   |   |   |   |   |   |
|     Basic and      diluted                                |   | $                                | (0.01      | )      |                            | $      | (0.02 | ) |   |   |   |   |
|                                                                          |   |                             |       |   |                            |   |   |   |   |   |   |   |
| Weighted average number of common      shares outstanding - Basic and diluted |   |                             | 42,332,533 |   |                            |   | 11,719,875 |   |   |   |   |   |

----

|                                                                                                                  |   | Three Months Ended June      30, |     |   |   |   |
|-----------------------------------------------------------------------------------------------------------------------|--------|----------------------------------|----------|--------|--------|--------|
|                                                                                                                  |   | 2008                             |     |   | 2007   |   |   | Cumulative from Inception      (February 9, 2007) through June 30, 2008 |   |
| Cash flows from operating      activities:                                                                            |   |                             |     |   |   |   |   |   |   |
|     Net      loss                                                                                 |   | $                                | (296,633 | )      |   | $      | (254,941 | ) |   | $ | (2,033,313 | ) |
|     Adjustments      to reconcile net loss to cash used in operating      activities:             |   |                             |     |   |   |   |   |   |   |   |   |   |
|         Depreciation      and amortization                                    |   |                             | 6,888    |   |   |   | - |   |   |   | 16,252 |   |
|         Amortization      of deferred financing costs                         |   |                             | 1,251    |   |   |   | - |   |   |   | 3,336 |   |
|         Non-cash      compensation expense relating to license agreement      |   |                             | -        |   |   |   | 119,900 |   |   |   | 119,900 |   |
|         Impairment      of license agreement                                  |   |                             | -        |   |   |   | 80,100 |   |   |   | 80,100 |   |
|         Beneficial      conversion cost on convertible notes                  |   |                             | 22,054   |   |   |   | - |   |   |   | 22,054 |   |
|         Share-based      compensation                                         |   |                             | 58,750   |   |   |   | 880 |   |   |   | 653,161 |   |
|         Non-cash      acquisition costs of subsidiary                         |   |                             | -        |   |   |   | - |   |   |   | 220,000 |   |
|         Changes      in assets and liabilities:                               |   |                             |     |   |   |   |   |   |   |   |   |   |
|             Other      current assets                     |   |                             | -        |   |   |   | - |   |   |   | (15,000 | ) |
|             Accounts      payable                         |   |                             | (5,491   | )      |   |   | 4,440 |   |   |   | 103,697 |   |
|             Accounts      payable – related parties |   |                             | 12,414   |   |   |   | 27,155 |   |   |   | 124,197 |   |
|             Accrued      liabilities                      |   |                             | 42,827   |   |   |   | 10,045 |   |   |   | 167,557 |   |
| Net cash used in operating      activities                                                                            |   |                             | (157,940 | )      |   |   | (12,421 | ) |   |   | (538,058 | ) |
| Cash flows from investing      activities:                                                                            |   |                             |     |   |   |   |   |   |   |   |   |   |
|     Investment      in option agreement                                                           |   |                             | -        |   |   |   | - |   |   |   | (20,000 | ) |
|     Property      and equipment                                                                   |   |                             | -        |   |   |   | - |   |   |   | (5,145 | ) |
| Net cash used in investing      activities                                                                            |   |                             | -        |   |   |   | - |   |   |   | (25,145 | ) |
| Cash flows from financing      activities:                                                                            |   |                             |     |   |   |   |   |   |   |   |   |   |
|     Proceeds      from notes payable – related parties                                      |   |                             | -        |   |   |   | 20,000 |   |   |   | 223,000 |   |
|     Repayment      of notes payable – related party                                         |   |                             | -        |   |   |   | - |   |   |   | (13,000 | ) |
|     Proceeds      from sale of common stock                                                       |   |                             | 90,000   |   |   |   | 1,165 |   |   |   | 91,165 |   |
|     Proceeds      from exercise of stock options                                                  |   |                             | 67,239   |   |   |   | - |   |   |   | 270,048 |   |
| Net cash provided by financing      activities                                                                        |   |                             | 157,239  |   |   |   | 21,165 |   |   |   | 571,213 |   |
| Net change in      cash                                                                                          |   |                             | (701     | )      |   |   | 8,744 |   |   |   | 473 |   |
| Cash and cash equivalents,      beginning of period                                                                   |   |                             | 1,174    |   |   |   | - |   |   |   | - |   |
| Cash and cash equivalents, end of      period                                                                         |   | $                                | 473      |   |   | $      | 8,744 |   |   | $ | 473 |   |
|                                                                                                                  |   |                             |     |   |   |   |   |   |   |   |   |   |
| Supplemental      disclosures:                                                                                        |   |                             |     |   |   |   |   |   |   |   |   |   |
|     Interest      paid                                                                            |   | $                                | -        |   |   | $      | - |   |   | $ | 3,834 |   |
|     Income      taxes paid                                                                        |   | $                                | -        |   |   | $      | - |   |   | $ | - |   |
|                                                                                                                  |   |                             |     |   |   |   |   |   |   |   |   |   |
| Non-cash financing      activities:                                                                                   |   |                             |     |   |   |   |   |   |   |   |   |   |
| Discount on convertible      notes                                                                                    |   |                             | 397,985  |   |   |   |   |   |   |   | 397,985 |   |
| Stock issued for accounts      payable                                                                                |   |                             | 28,500   |   |   |   |   |   |   |   | 28,500 |   |
|     Cancellation      of stock certificate                                                        |   | $                                | -        |   |   | $      | - |   |   | $ | 300 |   |
|     Issuance      of note payable for license agreement                                           |   | $                                | 200,000  |   |   | $      | 200,000 |   |   | $ | 200,000 |   |
|     Stock      issued for prepaid investor relation services                                      |   | $                                | -        |   |   | $      | - |   |   | $ | 73,800 |   |

----

----

|                                                   |   | Before 1:80Reverse Split |          |   | After 1:80Reverse Split |   |
|--------------------------------------------------------|--------|--------------------------|---------------|--------|-------------------------|--------|
| Common shares outstanding prior to      reverse merger |   |                     | 49,946,724    |   |                    |   | 624,334 |   |
| Initial shares issued pursuant to      reverse merger  |   |                     | 450,053,276   |   |                    |   | 5,625,666 |   |
| Shares issued subsequent to      shareholder meeting   |   |                     | 2,757,786,724 |   |                    |   | 34,472,334 |   |
| Total shares      outstanding                          |   |                     | 3,257,786,724 |   |                    |   | 40,722,334 |   |

----

| ITEM 2. | MANAGEMENTS DISCUSSION AND      ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF      OPERATIONS |
|---------|------------------------------------------------------------------------------------------------|

| ITEM 3. | QUANTITATIVE AND QUALITATIVE      DISCLOSURES ABOUT MARKETRISK |
|---------|----------------------------------------------------------------|

----

| ITEM 4. | CONTROLS AND      PROCEDURES |
|---------|------------------------------|

----

PART II.  OTHERINFORMATION

----

ITEM 6. EXHIBITS

| Exhibit No. | Description                                                                                                                                                                                                                                                                              |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.1        | Agreement and Plan of      Reorganization between Dragon Gold Resources, Inc. and Secure Voice      Communications, Inc. dated May 31, 2007, filed as an exhibit to the      Company’s Annual Report on Form 10-KSB for the year ended March 31, 2007,      filed on June 6, 2007. |
| 10.2        | Edgeline Holdings, Inc. 2007 Stock      Option Plan filed as an exhibit to the Company’s Registration Statement on      Form S-8 filed on July 25, 2007.  *                                                                                                              |
| 10.3        | Employment agreement dated May 10,      2007, with J. Leonard Ivins filed as an exhibit to the Company’s Annual      Report on Form 10-KSB for the year ended March 31, 2007, filed on June 6,      2007.  *                                                             |
| 10.4        | Investment Agreement dated      December 20, 2007, between Registrant and Dutchess Private Equities Fund,      Ltd. Filed as an exhibit to the Company’s Form 8-K dated December 26,      2007.                                                                                    |
| 10.5        | Registration Rights Agreement      dated December 20, 2007, between Registrant and Dutchess Private Equities      Fund, Ltd. Filed as an exhibit to the Company’s Form 8-K dated December      26, 2007.                                                                           |
| 10.6        | Amended and Restated Articles of      Incorporation filed as an exhibit to the Company’s Definitive Information      Statement dated February 15, 2008.                                                                                                                            |
| 10.7        | Amendment to Stock Purchase      Agreement with Intertech Bio, Inc.                                                                                                                                                                                                                      |
| 21.1        | Subsidiaries of the Registrant      provided herewith.                                                                                                                                                                                                                                   |
| 31.1        | Certification of J. Leonard      Ivins.  Provided herewith.                                                                                                                                                                                                                    |
| 31.2        | Certification of Steven M.      Plumb.  Provided herewith.                                                                                                                                                                                                                     |
| 32.1        | Certification for Sarbanes-Oxley      Act of J. Leonard Ivins.  Provided    Herewith.                                                                                                                                                                                          |
| 32.2        | Certification for Sarbanes-Oxley      Act of Steven M. Plumb.  Provided    Herewith.                                                                                                                                                                                           |

----

SIGNATURES

----

EXHIBIT 10.7

----

| Investor    Name                         |   |   |   |
|------------------------------------------|--------|--------|--------|
|  Waldemar    Priebe                 |   | $      | 29,673 |   |
|  Timothy    Madden                  |   | $      | 8,152  |   |
|  Ryan Cravey                        |   | $      | 7,414  |   |
|  Houston Pharmaceuticals,      Inc. |   | $      | 43,761 |   |